Federal Register of Legislation - Australian Government

Primary content

No. 53 of 2022 Determinations/Veterans' Entitlements as made
This instrument amends the Statement of Principles concerning hypopituitarism (Reasonable Hypothesis) (No. 11 of 2019).
Administered by: Veterans' Affairs
Registered 02 May 2022
Table of contents.

RMA-Red

 

Amendment Statement of Principles

concerning

HYPOPITUITARISM
(Reasonable Hypothesis)

(No. 53 of 2022)

The Repatriation Medical Authority determines the following Amendment Statement of Principles under subsections 196B(2) and (8) of the Veterans' Entitlements Act 1986.

 

Dated    29 April 2022

 

 

 

 

 

The Common Seal of the
Repatriation Medical Authority
was affixed to this instrument
at the direction of:

 

 

 

Professor Terence Campbell AM

Chairperson

 

  

Contents

1          Name........................................................................................................................................... 3

2          Commencement........................................................................................................................ 3

3          Authority..................................................................................................................................... 3

4          Amendment............................................................................................................................... 3

 

 


 

1               Name

This is the Amendment Statement of Principles concerning hypopituitarism (Reasonable Hypothesis) (No. 53 of 2022).

2               Commencement

This instrument commences on 30 May 2022.

3               Authority

This instrument is made under subsections 196B(2) and (8) of the Veterans' Entitlements Act 1986.

4               Amendment

The Statement of Principles concerning hypopituitarism (Reasonable Hypothesis) (No. 11 of 2019) (Federal Register of Legislation No. F2019L00009) is amended in the following manner:

 

Section

Amendment

9(16)

Replace the existing factor in subsection 9(16) with the following:

taking an immune checkpoint inhibitor or an interferon within the one year before the clinical onset of hypopituitarism;

Note: immune checkpoint inhibitor is defined in the Schedule 1 - Dictionary.

9(34)

Replace the existing factor in subsection 9(34) with the following:

taking an immune checkpoint inhibitor or an interferon within the one year before the clinical worsening of hypopituitarism;

Note: immune checkpoint inhibitor is defined in the Schedule 1 - Dictionary.

Schedule 1 – Dictionary

Replace the existing definition of "immune checkpoint inhibitor" with the following:

immune checkpoint inhibitor means a form of cancer immunotherapy that uses monoclonal antibodies targeting the immune checkpoint proteins. Examples include ipilimumab, tremelimumab, nivolumab and pembrolizumab.